Host: The Japanese Society of Toxicology
In this session, we will focus on gastrointestinal (GI) toxicity and present some case studies to demonstrate utility of advanced human in vitro GI models and preclinical and clinical safety biomarkers for addressing drug-related GI toxicity. We will also discuss the current landscape of microbiome research as gut microbiomes have been reported to alter drug safety or efficacy. Overall, the discussion will focus on how novel models and biomarkers are being positioned today and in the future to support drug discovery and development.